Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

Valeant Pharmaceuticals (VRX.TO)

PAST TOP PICK
(Was a top pick on Dec 10 down 6%) Got stopped out and no longer own.
TOP PICK
Tremendous pipeline of new products going forward. Volatile. Good execution.
TOP PICK
Good possibilities of getting product into market, so possibly will hve great upside. Volatile. Prefers over Angiotech.
DON'T BUY
A little high. Solid company. Be careful of stock options. Would buy at $50/60.
BUY
A good long term hold.
BUY ON WEAKNESS
Good business model. Being checked for submarine patents. Good pipeline. Buy in high $60's.
BUY
Has dropped to a reasonable level. They have REAL products.
TOP PICK
Good short term buy. Gave good earnings guidance.
BUY
A good entry point. A good core holding. Biotechs can be volatile.
BUY
Balance sheet has been cleaned up. Stock price has dropped unnecessarily. Cheap.
BUY
Good price. Company is strong.
DON'T BUY
Have some legal issues in the US. Expensive.
BUY
Volatile, but a good company.
BUY
Good, decent growth prospects.
TOP PICK
(Was a top pick on Nov 26 down 13%) At a good level. Volatile. Have used as a trading stock. Has been under pressure because of a US analyst.
Showing 646 to 660 of 714 entries